Legend Biotech Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Legend Biotech stock has a consensus rating of "Buy" and an average price target of $52.1. The average 1-year stock price forecast is 180.86% higher than the current stock price, while the lowest is $27 (+45.55%) and the highest is $80 (+331.27%).

Price Target: $52.1 (+180.86%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$27	$52.1	$56	$80
Change	+45.55%	+180.86%	+201.89%	+331.27%

Analyst Ratings

The average analyst rating for Legend Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	9	9	9	8	7	6
Buy	5	5	5	5	5	5
Hold	2	2	2	2	2	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	16	15	14	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $65	Buy	Reiterates	$65	+250.40%	Jul 28, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Reiterates $63 → $59	Buy	Reiterates	$63 → $59	+218.06%	Jul 27, 2026
Ashwani Verma UBS	UBS	Hold Downgrades $49 → $28	Hold	Downgrades	$49 → $28	+50.94%	Jul 24, 2026
Ziyi Chen Goldman Sachs	Goldman Sachs	Buy Maintains $41 → $41	Buy	Maintains	$41 → $41	+118.33%	Jul 16, 2026
Etzer Darout Barclays	Barclays	Buy Maintains $80	Buy	Maintains	$80	+331.27%	Jul 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.42B

from 1.03B

38.03%

from 1.03B

Revenue Next Year

1.81B

from 1.42B

27.54%

from 1.42B

EPS This Year

0.28

from -1.60

EPS Next Year

1.10

from 0.28

291.96%

from 0.28

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	68.83M	117.01M	285.10M	627.30M	1.03B	1.42B
Revenue Growth	-8.23%	70.00%	143.67%	120.03%	64.02%	38.03%
Gross Profit	68.83M	51.64M	140.90M	392.70M	620.80M	841.18M
Gross Margin	100.00%	44.14%	49.42%	62.60%	60.34%	59.23%
Operating Income	-394.02M	-458.05M	-528.10M	-305.10M	-136.50M	30.10M
Net Income	-403.58M	-446.35M	-518.30M	-177.00M	-296.80M	9.60M
EPS	-	-	-	-	-1.60	0.28
Forward PE	-	-	-	-	150.43	66.25
Free Cash Flow	-122.84M	-202.66M	-496.78M	-40.55M	-133.99M	-15.00M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	1.5B
Avg	1.4B
Low	1.4B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	41.9%
Avg	38.0%
Low	33.4%

EPS Forecast

Chart

EPS	2026	2027	2028
High	0.28
Avg	0.28
Low	0.28

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-